IX vs ECPG vs RPRX Stock Comparison

Orix, Encore Capital and Royalty Pharma Prices as of Nov 13, 2026 Peers: Industry group
IX Orix Corp
$34.39 -5.7% 1M +32.1% 1Y
Market cap
$37.82B
P/E
5.8x
Revenue (TTM)
$41.73B
Div. yield
–
Specialty Finance Financial Services
2 wins
ECPG Encore Capital Group Inc
$109.49 +8.6% 1M +124.2% 1Y
Market cap
$2.26B
P/E
6.4x
Revenue (TTM)
$1.99B
Div. yield
–
Specialty Finance Financial Services
6 wins
RPRX Royalty Pharma plc
$69.31 +17.5% 1M +74.5% 1Y
Market cap
$30.98B
P/E
46.1x
Revenue (TTM)
$2.62B
Div. yield
–
Specialty Finance Financial Services
2 wins

Head to Head

10 decided of 12

Encore Capital leads on 6 of the 12 questions below (Encore Capital 6, Orix 2, Royalty Pharma 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionIXECPGRPRXLeader
Larger companyMarket capitalisation $37.82B $2.26B $30.98B IX
Cheaper on earningsLower P/E, profitable companies only 5.8x 6.4x 46.1x IX
Cheaper on forward earningsLower price / next fiscal year consensus EPS 7.9x 6.5x 12.2x ECPG
Faster revenue growthRevenue growth, trailing twelve months -23.5% +27.2% +11.4% ECPG
More profitableNet margin, trailing twelve months 15.6% 17.7% 25.7% RPRX
Better return on capitalReturn on invested capital 2.8% 11.3% — ECPG
Less leveragedLower net debt / EBITDA — 5.1x — –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +32.1% +124.2% +74.5% ECPG
Better 5-year returnAnnualised price return, 5 years +10.6%/yr +13.2%/yr +10.6%/yr ECPG
Less volatileAnnualised volatility, 1 year 29.0% 41.1% 22.1% RPRX
Higher overall scoreMean of the five percentile scores vs peers 60/100 70/100 54/100 ECPG

Percentile Scorecard

IXECPGRPRX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisIXECPGRPRX
Valuation 78 #39 of 173 71 #51 of 173 17 #143 of 173
Growth 81 #33 of 169 91 #17 of 169 76 #42 of 169
Profitability 79 #34 of 156 83 #28 of 156 95 #9 of 156
Financial Health 57 #71 of 164 29 #116 of 164 72 #46 of 164
Shareholder Returns 5 #129 of 136 75 #35 of 136 10 #123 of 136
Overall 60 70 54
  • IX ranked among 176 companies in Lending and Credit
  • ECPG ranked among 176 companies in Lending and Credit
  • RPRX ranked among 176 companies in Lending and Credit

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodIXECPGRPRXSPY
1 month -5.7%+8.6%+17.5% -2.0%
3 months -14.3%+5.5%+18.3% -2.8%
6 months -6.2%+34.1%+31.1% +2.0%
Year to date +17.7%+101.5%+79.4% +10.6%
1 year +32.1%+124.2%+74.5% +12.2%
3 years +90.2%+147.9%+151.9% +68.1%
3 years, per year +23.9%+35.4%+36.1% +18.9%
5 years +65.3%+85.7%+65.3% +61.4%
5 years, per year +10.6%+13.2%+10.6% +10.1%
10 years +113.9%+329.4%— +248.5%
10 years, per year +7.9%+15.7%— +13.3%

Risk

MeasureIXECPGRPRXSPY
Volatility, 1Y 29.0%41.1%22.1% 13.6%
Downside volatility, 1Y 29.0%33.3%21.0% 13.9%
Beta vs S&P 500, 1Y 0.940.110.23 1.00
Return / volatility, 1Y 1.103.023.36 0.90
Max drawdown, 5Y -39.0%-62.5%-45.6% -25.4%
From 52-week high -16.8%-13.2%-1.0% -3.2%
52-week high $41.31$126.17$70.01 $779.14
52-week low $25.42$47.72$38.09 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleIXECPGRPRX
P/E now vs peer median 5.9xmedian 11.6x 6.7xmedian 11.6x 46.0xmedian 11.6x
P/S now vs peer median 0.9xmedian 2.5x 1.2xmedian 2.5x 15.2xmedian 2.5x
EV/EBITDA now vs peer median —median 9.5x 7.9xmedian 9.5x —median 9.5x
P/FCF now vs peer median —median 4.7x 15.1xmedian 4.7x 13.4xmedian 4.7x
P/B now vs peer median 1.2xmedian 0.7x 2.1xmedian 0.7x 4.1xmedian 0.7x
PEG now vs peer median 0.12median 0.32 0.03median 0.32 0.79median 0.32

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsIXECPGRPRX
Revenue $41.73B $1.99B $2.62B
Gross profit $26.62B – –
Operating income $2.88B $774.89M $1.50B
Net income $6.59B $350.91M $1.17B
Free cash flow – $151.46M $2.96B
R&D – – $251.40M
EPS (diluted) $5.82 $15.77 $1.21
Cash & equivalents $7.17B $158.43M $513.66M
Total debt $38.77B $4.24B $8.59B
Shares (diluted) 1.12B 22.26M 557.00M
Enterprise value $7.96B $1.53B $28.35B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricIXECPGRPRX
P/E 5.9x 6.7x 46.0x
P/FCF – 15.1x 13.4x
P/Operating cash flow – 13.0x 13.4x
P/S 0.9x 1.2x 15.2x
P/B 1.2x 2.1x 4.1x
P/Tangible book 1.2x 2.1x 4.1x
EV/EBITDA – 7.9x –
EV/EBIT 24.4x 8.2x 32.0x
EV/Revenue 1.7x 3.2x 18.3x
EV/FCF – 42.1x 16.2x
EV/Operating cash flow – 36.1x 16.2x
PEG (3Y EPS CAGR) 0.12 0.03 0.79

Growth

14 metrics
MetricIXECPGRPRX
Revenue growth (1Y) -23.5% 27.2% 11.4%
Revenue CAGR (3Y) -3.2% 19.0% 4.0%
Gross profit growth (1Y) 2,245% – –
Gross profit CAGR (3Y) 7.8% – –
Operating income growth (1Y) 12.9% 142.9% -2.4%
Operating income CAGR (3Y) 4.5% 49.6% 55.6%
Net income growth (1Y) 120.4% 877.6% -9.9%
Net income CAGR (3Y) 44.7% 246.7% 46.6%
EPS growth (1Y) 124.9% 921.8% -11.6%
EPS CAGR (3Y) 47.6% 256.9% 57.9%
Operating cash flow growth (1Y) – 10.3% 23.1%
Operating cash flow CAGR (3Y) – 0.9% 2.0%
Free cash flow growth (1Y) – 14.7% 23.1%
Free cash flow CAGR (3Y) – 2.9% 2.0%

Profitability

14 metrics
MetricIXECPGRPRX
Gross margin 63.8% – –
EBITDA margin – 40.4% –
Operating margin 6.9% 39.0% 57.1%
Pretax margin 21.5% 22.8% 44.8%
Net margin 15.6% 17.7% 25.7%
FCF margin – 7.6% 113.1%
Operating cash flow margin – 8.9% 113.1%
Return on equity 21.1% 32.5% 12.0%
Return on assets 6.2% 6.2% 6.0%
Return on invested capital 2.8% 11.3% –
Return on capital employed – – 8.1%
Asset turnover 0.4x 0.4x 0.1x
Cash conversion (OCF / net income) – 0.5x 2.5x
Stock comp / revenue – 1.0% –

Financial Health

11 metrics
MetricIXECPGRPRX
Debt / assets 39.1% 74.6% 44.1%
Debt / equity 1.2x 3.9x 0.9x
Net debt / EBITDA – 5.1x –
Debt / FCF – 28.0x 2.9x
Liabilities / assets 66.9% 81.0% 49.7%
Equity / assets 33.1% 19.0% 50.3%
Interest coverage 2.4x 2.6x 4.0x
Current ratio – – 1.3x
Quick ratio – – 0.5x
Cash ratio – – 0.5x
Altman Z-score – – 3.06

Shareholder Returns

7 metrics
MetricIXECPGRPRX
Dividend yield 1.1% – 1.6%
Net buyback yield -3.5% 5.6% –
Shareholder yield -2.3% 5.6% 1.6%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusIXECPGRPRX
Forward P/E 7.9xFY2026 6.5xFY2026 12.2xFY2026
EPS, next fiscal year $4.36FY2026 $16.72FY2026 $5.69FY2026
EPS growth, next FY +71.7%FY2026 +53.3%FY2026 +17.8%FY2026
EPS growth, the year after -24.3% +5.4% +9.5%
Revenue, next fiscal year $22.52BFY2026 $1.92BFY2026 $3.78BFY2026
Revenue growth, next FY +6.6%FY2026 +8.4%FY2026 +16.3%FY2026
Revenue growth, the year after -2.1% +10.5% +7.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersIXECPGRPRX
Held by institutions 3.3% 100.0% 82.2%
Institutions holding 320 283 643
Change in shares held, QoQ +9.5% -3.8% +2.7%
Institutions buying 211 159 395
Institutions selling 57 91 179
Buyers to sellers 3.70 1.75 2.21

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

IXECPGRPRX
IX 1.00 0.02 0.14
ECPG 0.02 1.00 0.04
RPRX 0.14 0.04 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, IX, ECPG and RPRX?

Orix (IX) is the largest by market capitalisation: Orix (IX) $37.82B, Encore Capital (ECPG) $2.26B, Royalty Pharma (RPRX) $30.98B.

Which stock is cheaper, IX, ECPG and RPRX?

Orix (IX) trades on the lowest price-to-earnings ratio (Orix (IX) 5.8x, Encore Capital (ECPG) 6.4x, Royalty Pharma (RPRX) 46.1x). On next year's consensus earnings, Encore Capital (ECPG) is cheapest (Orix (IX) 7.9x, Encore Capital (ECPG) 6.5x, Royalty Pharma (RPRX) 12.2x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Encore Capital (ECPG) grew revenue fastest over the trailing twelve months: Orix (IX) -23.5%, Encore Capital (ECPG) +27.2%, Royalty Pharma (RPRX) +11.4%.

Which company is more profitable?

Royalty Pharma (RPRX) has the highest net margin (Orix (IX) 15.6%, Encore Capital (ECPG) 17.7%, Royalty Pharma (RPRX) 25.7%). On return on invested capital, Encore Capital (ECPG) leads (Orix (IX) 2.8%, Encore Capital (ECPG) 11.3%).

Which stock has performed better?

Over the past year Encore Capital (ECPG) returned the most: Orix (IX) +32.1%, Encore Capital (ECPG) +124.2%, Royalty Pharma (RPRX) +74.5%. Over five years, Encore Capital (ECPG) compounded fastest (Orix (IX) +10.6%/yr, Encore Capital (ECPG) +13.2%/yr, Royalty Pharma (RPRX) +10.6%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Royalty Pharma (RPRX) has been the steadiest (Orix (IX) 29.0%, Encore Capital (ECPG) 41.1%, Royalty Pharma (RPRX) 22.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, IX, ECPG and RPRX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Encore Capital (ECPG) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.